Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo

No abstract is available for this paper.

• Publication year

  1994

• Venue

  NeuroReport

• Publication date

  1994-10-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001756-199410270-00042PMID 7865766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat

  2004cited by this paper
• NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

  1993cited by this paper
• Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+.

  1992cited by this paper
• In vivo protection of striatum from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.

  1992cited by this paper
• Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.

  1992cited by this paper
• Potassium markedly potentiates the effect of veratridine on dopamine release from rat superfused striatal ribbons

  1992cited by this paper
• Effects of riluzole (2‐amino‐6‐trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems

  1992cited by this paper
• MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats

  1992cited by this paper
• Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre

  1991cited by this paper
• Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

  1991cited by this paper
• The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).

  1990cited by this paper
• Use of Calcium Antagonism for the Characterization of Drug‐Evoked Dopamine Release from the Brain of Conscious Rats Determined by Microdialysis

  1989cited by this paper
• The use of in vivo brain dialysis of dopamine, acetylcholine, amino acids and lactic acid in studies on the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1988cited by this paper
• The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis

  1987cited by this paper
• Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+.

  1986cited by this paper
• 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper

• Neuroprotection in Parkinson's Disease: A Systematic Review of thePreclinical Data

  2012influential citation
• Pre‐synaptic glutamate‐induced activation of DA release in the striatum after partial nigral lesion

  2010cites this paper
• Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

  2010cites this paper
• The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs

  2009cites this paper
• The evolution of pharmacological treatment for Parkinson's disease.

  2008cites this paper
• Antiglutamatergic drugs in the treatment of Parkinson's disease.

  2007cites this paper
• Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction

  2003cites this paper
• Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence

  2002cites this paper
• Methyl-4-phenylpyridinium (MPP(+))-evoked dopamine release from rat striatal slices: possible roles of voltage-dependent calcium channels and reverse dopamine transport.

  2001cites this paper
• Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

  2001cites this paper
• Neuroprotective effect of riluzole in MPTP-treated mice.

  2001cites this paper
• Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice

  2001cites this paper
• The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.

  2000cites this paper
• Implication of the Subthalamic Nucleus in the Pathophysiology and Pathogenesis of Parkinson's Disease

  2000cites this paper
• Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice

  2000cites this paper
• The Neuroprotective Agent Riluzole Activates the Two P Domain K+ Channels TREK-1 and TRAAK

  2000cites this paper
• Riluzole Reduces Brain Swelling and Contusion Volume in Rats Following Controlled Cortical Impact Injury

  2000cites this paper
• The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.

  2000influential citation
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• Pharmacology: Ouabain‐induced Increase in Dopamine Release from Mouse Striatal Slices is Antagonized by Riluzole

  1998cites this paper
• Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.

  1998cites this paper
• Experimental Models of Parkinson's Disease: From the Static to the Dynamic

  1998cites this paper
• Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat

  1998cites this paper
• Riluzole, a glutamate release inhibitor, and motor behavior

  1998cites this paper
• Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury.

  1997cites this paper
• A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

  1997cites this paper
• Riluzole, a Novel Neuroprotective Agent, Attenuates Both Neurologic Motor and Cognitive Dysfunction Following Experimental Brain Injury in the Rat

  1996cites this paper
• Alterations of dopamine release by rat caudate putamen tissues superfused with α2‐Macroglobulin

  1996cites this paper
• Alteration of dopamine release by rat caudate putamen tissues superfused with alpha 2-macroglobulin.

  1996cites this paper
• Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.

  1996cites this paper
• Neurodegenerative disorders: clues from glutamate and energy metabolism.

  1996cites this paper
• 3−Nitropropionic Acid Exacerbates [3H]GABA Release Evoked by Glucose Deprivation in Rat Striatal Slices

  1996cites this paper
• The pharmacology and mechanism of action of riluzole

  1996cites this paper
• Riluzole Anesthesia: Use-Dependent Block of Presynaptic Glutamate Fibers

  1996cites this paper
• Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission.

  1995cites this paper
• Excitatory amino acid receptors and neurodegeneration.

  1995cites this paper
• Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice.

  1995cites this paper
• Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.

  1995cites this paper
• Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.

  1995cites this paper
• Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.

  1994cites this paper